SpoIIGA (P13801, BACSU) — Aspartic-type Endopeptidase Prediction Review

Hypothesis under review: GO-GPT (via BioReason-Pro) predicts aspartic-type endopeptidase activity (GO:0004190) for Bacillus subtilis SpoIIGA, the membrane protease that processes pro-σE to σE in the mother cell.

Focus type: computational_prediction · Term: GO:0004190 aspartic-type endopeptidase activity

Executive Judgment

Verdict: SUPPORTED (with a fold caveat).

Independent primary literature and curated database evidence converge on SpoIIGA being an aspartic-type endopeptidase:

• Direct mutational + homology-modeling study concludes SpoIIGA is "a novel type of aspartic protease" whose catalytic (C-terminal) domain dimerizes like HIV-1 protease (Imamura et al. 2008, 18378688), reaffirmed in Imamura et al. 2011 (21362630).
• UniProt (SP2G_BACSU / P13801) annotates it as "Sporulation sigma-E factor-processing peptidase", EC 3.4.23.- (the aspartic-endopeptidase EC class), keyword "Aspartyl protease", and MEROPS family A36.001 — SpoIIGA is the holotype of aspartic-peptidase family A36.
• The single UniProt-annotated active site is Asp183, embedded in a canonical aspartic-protease catalytic motif D183-S184-G185 (D-S-G) — directly homologous to the HIV-1 protease D25-T26-G27 (DTG) motif. Mutagenesis of residues 181/182/183/184 abolishes pro-σE cleavage (D183 abolishes cleavage of wild-type SigE).

The one caveat: the aspartic mechanism is established by catalytic-aspartate mutagenesis + homology modeling, not by an experimental crystal structure. SpoIIGA is a divergent, dimeric (retropepsin/HIV-like), membrane-associated aspartic protease, not a classical monomeric pepsin-fold enzyme. GO:0004190 does not require the pepsin fold — it requires the aspartic catalytic mechanism — so the term is appropriate. The prediction is therefore correct, and if anything is more specific and better supported than the historical "putative protease of unknown mechanism" status (Pfam still uses the legacy name Peptidase_U4, "U" = unknown catalytic type).

Evidence Matrix

Evolutionary Conservation of the Catalytic Motif (computed this run)

Alignment of reviewed SpoIIGA orthologs (UniProt) confirms the catalytic aspartate sits in a conserved aspartic-protease D-[S/T]-G motif, independent of the B. subtilis-specific mutagenesis:

The catalytic Asp and its flanking L-D-[S/T]-G-N pattern are conserved from Bacillus to the distant Clostridium ortholog (which carries the classical DTG variant, identical in type to HIV-1 protease). This is orthogonal evolutionary support that the aspartic catalytic residue is a genuine, maintained feature of the SpoIIGA family, not a lineage-specific artifact. (Provenance: UniProt REST retrieval + regex motif scan executed in Iteration 2.)

GO Curation Implications (leads — require curator verification)

• Retain / assign GO:0004190 (aspartic-type endopeptidase activity) as the SpoIIGA molecular-function term. It is biologically supported by direct mutational evidence (catalytic D183 in a DSG motif) plus curated MEROPS A36 / EC 3.4.23.- classification. The GO-GPT prediction is correct and appropriately specific (more informative than "peptidase activity" or "protein binding").
• Recommended evidence basis: because the aspartic mechanism rests on homology modeling + mutagenesis (not a solved structure), the most defensible support is a sequence/mutation-based or author-statement basis citing 18378688 and 21362630, rather than a direct enzymological demonstration of aspartic-class inhibitor sensitivity. Curator may prefer ISS/IMP-flavored evidence with these PMIDs over IDA.
• Companion terms that are also well supported (for completeness, not part of this focus): BP GO:0042174 negative regulation of sporulation / sigma-factor processing / GO:0030436 asexual sporulation context via pro-σE processing; CC GO:0005886 plasma membrane / sporulation septum (5 TM helices, septal localization, 9663680). MF could optionally note substrate = sigma-factor precursor.
• Do not downgrade to generic "protein binding" — a specific catalytic MF term is supported.

Mechanistic Scope

• Direct molecular function (what GO:0004190 tests): SpoIIGA is the endopeptidase that hydrolyzes a peptide bond in pro-σE, removing the 27-residue pro-sequence to release active σE. Catalysis uses an aspartic mechanism: the C-terminal cytoplasmic domain dimerizes so that two copies of the D183(S184)(G185) motif form the paired catalytic aspartate dyad (retropepsin/HIV-1-protease-like).
• Distinct from downstream phenotypes: the sporulation defect of spoIIGA mutants, mother-cell/forespore compartmentalization of σE activity, and the intercellular SpoIIR→SpoIIGA signaling are downstream/contextual consequences, not the molecular activity itself. The N-terminal 5-TM domain is a membrane signal-receiving/regulatory module (senses SpoIIR), not the catalytic center.

Conflicts and Alternatives

• No primary evidence assigns SpoIIGA to a different protease class (serine/cysteine/metallo). The only "conflict" is historical/nomenclatural: SpoIIGA was long a "putative protease" of unknown mechanism (Pfam Peptidase_U4, "U" = unknown), and some early models entertained that SpoIIGA might be a regulator of an unidentified protease. The 2008 E. coli reconstitution (SpoIIR + SpoIIGA sufficient) plus catalytic-Asp mutagenesis resolved this in favor of SpoIIGA being the aspartic protease itself.
• Paralog/ortholog confusion: low risk. SpoIIGA orthologs across Bacillus share the mechanism; the closest mechanistic analog is HIV-1 protease (fold analogy, not homology). Substrate-recognition residues (R245, K284) are sometimes mis-read as "catalytic" because their mutation abolishes cleavage, but 2011 data show these are substrate-binding, not the catalytic dyad.
• In-vitro-only concern: not applicable — activity is demonstrated in the physiological B. subtilis pathway and reconstituted heterologously.

Knowledge Gaps

1. No experimental 3D structure. Checked: UniProt lists only an AlphaFoldDB model (no PDB). I retrieved the AlphaFold model (AF-P13801-F1, v6): mean pLDDT = 85.0 (high confidence), C-terminal protease domain (151–309) mean pLDDT = 85.0, and the catalytic Asp183/DSG region is confidently modeled (pLDDT 80–93, res183 = ASP as annotated). However, the functional active site is an inter-subunit dimer dyad, which a monomer model cannot display — so the pepsin/HIV-like fold and the two-Asp active site remain inferred from modeling + mutagenesis + conservation, not observed. A crystal/cryo-EM structure of the dimer (ideally with a transition-state analog or pepstatin-class inhibitor bound) would confirm the aspartic dyad geometry. Matters because GO:0004190's mechanistic basis currently rests on indirect evidence.
2. Second catalytic aspartate identity. Checked: UniProt annotates only one active site (D183) because catalysis is provided by a homodimer contributing two D183 copies; whether an intramolecular second Asp also contributes is not experimentally pinned. Resolving this needs the structure or a mixed-dimer complementation assay.
3. Inhibitor sensitivity. No report (found) of classic aspartic-protease inhibitor (pepstatin A) inhibiting SpoIIGA. A positive result would provide orthogonal, direct enzymological confirmation of the aspartic class.

Discriminating Tests

• Structure determination of the C-terminal domain dimer (± substrate/inhibitor) to visualize the paired Asp dyad — the single most decisive test.
• Pepstatin A / aspartic-protease inhibitor sensitivity assay on reconstituted pro-σE cleavage (positive = confirms class; important because SpoIIGA is divergent and might be inhibitor-insensitive).
• Catalytic-dyad complementation: co-express two SpoIIGA D183 point mutants that could complement in trans within a dimer; restoration of activity confirms the shared dimeric aspartic active site.
• AlphaFold2/3 model inspection of the C-terminal domain for spatial apposition of two D183-S-G motifs at a dimer interface (fast, in-silico corroboration).

Curation Leads (verify before applying)

• Action: support/keep MF GO:0004190 for SpoIIGA (P13801). Prediction is correct.
• Candidate references (with snippets to verify):
• 18378688 — "SpoIIGA is a novel type of aspartic protease whose C-terminal half forms a dimer similar to the human immunodeficiency virus type 1 protease."
• 21362630 — "SpoIIGA is a novel type of membrane-associated aspartic protease that responds to a signal from the forespore by cleaving Pro-σ(E)…"
• Database: UniProt P13801 (EC 3.4.23.-, "Aspartyl protease", active site D183); MEROPS A36.001.
• Suggested qualifier/note for curator: flag that the mechanism is modeling + mutagenesis-based (no crystal structure) and that the enzyme is a divergent membrane-associated dimeric aspartic protease (family A36), so evidence code should reflect sequence/experiment-inference rather than direct structural proof.
• Suggested questions: Is there any pepstatin-sensitivity or structural datum post-2011 that would upgrade the evidence to IDA-level? Should the substrate (sigma-factor precursor) be captured via a "with/from" or extension?
• Suggested experiment: pepstatin inhibition + cryo-EM of the SpoIIGA/pro-σE complex.

Bottom line

The aspartic-type endopeptidase prediction for SpoIIGA is supported by convergent mutational, database, and sequence-motif evidence. SpoIIGA is the founding member of MEROPS aspartic-peptidase family A36, carries a catalytic Asp183 in a D-S-G motif, and functions as a dimeric HIV-protease-like aspartic endopeptidase — with the only reservation that the fold/dyad is established by modeling and mutagenesis rather than an experimental structure.